Barclays
ENGN icon

Barclays’s enGene Therapeutics ENGN Stock Holding History

Barclays’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Buy
282,515
+282,173
+82,507% +$1.15M ﹤0.01% 3245
2026
Q1 		$2.33K Buy
+342
New +$3.04K ﹤0.01% 4837

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Barclays's ENGN Position: Q2 2026 in Review

Barclays increased its enGene Therapeutics (ENGN) stake by 82,507% in Q2 2026, buying an estimated $1.15M and bringing the position to 282,515 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #3245.

Barclays first reported a position in ENGN in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Barclays held 282,515 shares of enGene Therapeutics worth $489K as of Q2 2026.
  • Barclays bought 282,173 enGene Therapeutics shares in Q2 2026, an estimated $1.15M.
  • enGene Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3245 holding.
  • Barclays first reported a position in enGene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.